The Cardiopulmonary Complications of Vaping
Access to this document is restricted. Some items have been embargoed at the request of the author, but will be made publicly available after the "No Access Until" date.
During the embargo period, you may request access to the item by clicking the link to the restricted file(s) and completing the request form. If we have contact information for a Cornell author, we will contact the author and request permission to provide access. If we do not have contact information for a Cornell author, or the author denies or does not respond to our inquiry, we will not be able to provide access. For more information, review our policies for restricted content.
Electronic cigarettes, also known as e-cigarettes or vapes, have risen in popularity recently, especially among teenagers and young adults, because many believe they are safer than regular cigarettes. However, research has shown that the use of e-cigarettes can still lead to significant pulmonary and cardiovascular risks. E-liquids usually contain propylene glycol, vegetable glycerin, nicotine, flavorings, and sometimes tetrahydrocannabinol or other additives. When these ingredients are heated, they can produce harmful chemicals such as reactive aldehydes and other toxins that cause inflammation and other long-term effects. Studies have found a positive correlation between the use of e-cigarettes and oxidative stress, inflammation, and endothelial damage. Research has also linked vaping to an increase of reactive oxygen species in the blood of people like those of traditional tobacco smokers. The 2019-2020 outbreak of e-cigarette or vaping-associated lung injury, which was strongly connected to the unregulated presence of tetrahydrocannabinol and vitamin E acetate, highlighted the serious risks of these products. Our aim is to examine the health and economic burdens posed by e-cigarette use and challenge the idea that they are a "safer" alternative to traditional tobacco smoking.